
CT26.CL25
17 303,00Kč
Cena bez DPH: 14 300,00Kč
- Výrobce: Cytion
- Kód výrobce: CYT-305353
Dostupné možnosti
The CT26.CL25 cell line is a murine colon carcinoma model derived from the parental CT26 cell line, which is a chemically induced, undifferentiated colon carcinoma originating from BALB/c mice. CT26.CL25 has been genetically modified to express the β-galactosidase (β-gal) protein, making it an excellent model for studying tumor immunology and immunotherapy, particularly in the context of tumor-associated antigens (TAAs). This modification allows for specific immunological studies targeting β-gal as a neoantigen, facilitating research into the mechanisms of tumor immune evasion and the development of cancer vaccines or adoptive cell therapies. CT26.CL25 has been employed in preclinical models to investigate immune responses and the efficacy of immunotherapies, such as the use of dendritic cells (DCs) loaded with tumor-associated antigens. Studies have shown that immunization strategies using DCs pulsed with peptides derived from retroviral antigens, like gp70, can elicit robust anti-tumor immune responses. In experimental models, the activation of CD8+ cytotoxic T lymphocytes (CTLs) specific for gp70 was observed, demonstrating the cell line's utility in testing immunotherapeutic approaches. However, the immunization with such peptide-loaded DCs has shown limitations, particularly in treating established metastases, highlighting the challenges in translating prophylactic immune responses into therapeutic efficacy. Additionally, CT26.CL25 is often used in research to test the efficacy of combined immunotherapy approaches, such as the use of immune checkpoint inhibitors or cancer vaccines. For instance, studies have evaluated the impact of metronomic chemotherapy combined with immune checkpoint inhibitors, where the induction of immunogenic cell death (ICD) in CT26.CL25 has been crucial for enhancing the anti-tumor immune response. These investigations have demonstrated that targeting immune checkpoints can synergize with chemotherapy to increase tumor rejection rates and establish long-term immunological memory. Intestine cancer cell lines, Colon, Adenocarcinoma, Growth Conditions: Adherent, Biosafety level: BSL 1
Technické specifikace | |
Doprava a skladování | Adherent |
Poznámka k dopravě | Dopravné k objednávce je závislé na BLS třídě dodávaných produktů a na konkrétních podmínkách přepravy. Před objednáním nás prosím kontaktujte a naši pracovníci Vám vždy cenu dopravy vyčíslí pro každý jednotlivý případ. Každá viála obsahuje celkem přibližně 3 miliony adherentních buněk nebo 5 milionů suspenzních buněk s typickou životaschopností po rozmrazení v rozmezí 80-95 %. Tyto údaje slouží jako obecné vodítko; ačkoli dodržujeme přísné normy kvality, přesné počty buněk a životaschopnost se mohou lot-to-lot lišit a nejsou zaručeny. |
Vlastnosti | |
Původ | Mouse |
Specifita | Intestine cancer cell lines |